Brief: Rigel Announces Closing Of Licensing Agreement For Veppanu (Vepdegestrant)
16/06/2026 21:05
BRIEF-Rigel Announces Closing Of Licensing Agreement For Veppanu (Vepdegestrant) June 16 (Reuters) - Rigel Pharmaceuticals Inc RIGL.O:
RIGEL ANNOUNCES CLOSING OF LICENSING AGREEMENT FOR VEPPANU™ (VEPDEGESTRANT)
Source text: ID:nPn9xlLPva
Further company coverage: RIGL.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Rigel Pharmaceuticals
See all newsU.S. RESEARCH ROUNDUP- Berkshire Hathaway, Exxon Mobil, Honeywell Technologies
Rigel Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Rigel Pharmaceuticals Q2 revenue rises on strong product demand
Brief: Rigel Pharmaceuticals - Appoints Alison L. Hannah As Executive Vice President And Chief Medical Officer Effective July 1, 2026 - SEC Filing
Brief: Rigel Announces Closing Of Licensing Agreement For Veppanu (Vepdegestrant)